The slow progression of diabetic retinopathy makes it difficult to assess the effects of intervention therapy. (Br_J Ophthalmol 1995; 79: 35-37) North Staffordshire Royal Infirmary, Princes Road,
The Diabetes Control and Complications
Trial (DCCT)I and 7 year follow up data from the Oslo Study2 have established that good glycaemic control slows progression of diabetic retinopathy. The size, complexity, and cost of the DCCT (estimated to be $168 million) illustrate the difficulty of answering questions of intervention in diabetic retinopathy, where progression in retinal topographic features occurs over many years. This suggests a need for surrogate markers of visual change.
Measures of visual pathway function may have such a role; visual pathway function assessed by either colour discrimination ability or electroretinography is abnormal in patients with insulin dependent diabetes mellitus (IDDM) with and without retinopathy. [3] [4] [5] [6] Moreover, in patients with retinopathy, electroretinography (ERG) may predict disease progression,7 and in aretinopathic IDDM patients, colour discrimination ability is affected by changes in glycaemic control For the pattern ERG, there were no significant differences between diabetic patients and controls in implicit times of the N35, P55, and N95 waves or in the interpeak amplitudes, N35-P55 and P55-N95 (Table 1) .
OSCILLATORY POTENTIALS
Oscillatory potential implicit times, particularly for the first and second potentials, were significantly delayed in the diabetic group ( Table 2) . Some of the differences in OP amplitudes reached only borderline statistical significance, and the lack of a general trend in the data suggested that the biological significance of these results was doubtful (Table 3 
